Arrowhead Pharmaceuticals Inc. (ARWR)

18.94
NASDAQ : Health Technology
Prev Close 19.46
Day Low/High 18.82 / 19.38
52 Wk Low/High 9.52 / 22.39
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 1.85B
EPS -0.70
P/E Ratio 278.00
Div & Yield N.A. (N.A)
Arrowhead Raises $6.2 Million Through Registered Direct Offering Of Common Stock And Warrants

Arrowhead Raises $6.2 Million Through Registered Direct Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has entered into a securities purchase agreement with institutional and individual investors to raise gross proceeds of approximately $6.

Arrowhead Research To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference

Arrowhead Research To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr.

Arrowhead To Report Fiscal 2012 Third Quarter Financial Results

Arrowhead To Report Fiscal 2012 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 third quarter ended June 30, 2012, on Monday, August 13, 2012 at 4:30 p.

Arrowhead Announces Dosing Of First Patient With Anti-Obesity Treatment Adipotide® In A Phase 1 Clinical Trial

Arrowhead Announces Dosing Of First Patient With Anti-Obesity Treatment Adipotide® In A Phase 1 Clinical Trial

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide®, a new class of treatment for ...

Arrowhead Announces New Study Demonstrating Rapid Improvement In Pro-Diabetic Metabolic Markers With Anti-Obesity Drug Candidate, Adipotide®

Arrowhead Announces New Study Demonstrating Rapid Improvement In Pro-Diabetic Metabolic Markers With Anti-Obesity Drug Candidate, Adipotide®

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes ...

Arrowhead Research Advances ARC-520 Into IND-Enabling Studies For The Treatment Of Hepatitis B And Provides Guidance On Development Timeline

Arrowhead Research Advances ARC-520 Into IND-Enabling Studies For The Treatment Of Hepatitis B And Provides Guidance On Development Timeline

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical ...

Arrowhead Presents Data On DPC System At TIDES 2012

Arrowhead Presents Data On DPC System At TIDES 2012

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.

Arrowhead Reports Fiscal 2012 Second Quarter Financial Results

Arrowhead Reports Fiscal 2012 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March 31,...

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)

Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides

Arrowhead Research Corporation Acquires Alvos Therapeutics And Proprietary Library Of Targeting Peptides

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced that it has acquired Alvos Therapeutics, Inc.

Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment

Arrowhead Releases White Paper On Hepatitis B Virus And Potential RNAi Treatment

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed...

Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics

Arrowhead Research Corporation And Axolabs GmbH Enter Into Strategic Alliance And Master Services Agreement For RNAi Therapeutics

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the...

Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011.

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity,...

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug...

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30,...

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S.

Arrowhead To Report Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead To Report Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.

Arrowhead Research Appoints Drs. David Lewis And David Rozema To Lead Operations At Madison, WI Facility

Arrowhead Research Appoints Drs. David Lewis And David Rozema To Lead Operations At Madison, WI Facility

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed David Lewis, Ph.

Arrowhead Research Announces 1-for-10 Reverse Stock Split

Arrowhead Research Announces 1-for-10 Reverse Stock Split

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse stock split of...

Leonardo Biosystems Receives Second $1.25 Million Investment From The Texas Emerging Technology Fund

Leonardo Biosystems Receives Second $1.25 Million Investment From The Texas Emerging Technology Fund

Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.

6 Stocks Hitting New 52-Week Highs

6 Stocks Hitting New 52-Week Highs

When a stock hits a new 52-week high, it often indicates a very strong uptrend.

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published In Science Translational Medicine Demonstrates Weight Loss In Obese Monkeys

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published In Science Translational Medicine Demonstrates Weight Loss In Obese Monkeys

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.

Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview...

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P.

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development programs of Ablaris Therapeutics, Inc.

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.

TheStreet Quant Rating: D (Sell)